Lululemon Athletica Inc. (LULU) PT Raised to $222 at Susquehanna

Lululemon Athletica Inc. (LULU) PT Raised to $218 at MKM Partners

MKM Partners analyst Roxanne Meyer raised the price target on Lululemon Athletica Inc. (NASDAQ: LULU) to $218.00 (from $217.00) while maintaining a Buy rating.

The analyst comments "While bottoms continue to drive growth, it is traffic-driven comps across channels, geographies, and genders that give us... More

KeyBanc Reiterates Sector Weight Rating on Lululemon Athletica Inc. (LULU)

KeyBanc analyst Edward Yruma reiterated a Sector Weight rating on Lululemon Athletica Inc. (NASDAQ: LULU) following the company's 2Q report.

Core womens grew +13% and mens grew a very strong +27%. We believe that mens presents a particularly compelling opportunity and remain... More

Lululemon Athletica Inc. (LULU) PT Raised to $214 at Cowen

Cowen analyst John Kernan raised the price target on Lululemon Athletica Inc. (NASDAQ: LULU) to $214.00 (from $200.00) while maintaining an Outperform rating.

The analyst commented, "Execution continues to give confidence in upside to FY19 guidance and long-term targets. Product cycle in women's and men's... More

Lululemon Athletica Inc. (LULU) PT Raised to $194 at Macquarie

Macquarie analyst Laurent Vasilescu raised the price target on Lululemon Athletica Inc. (NASDAQ: LULU) to $194.00 (from $159.00) while maintaining a Neutral rating.

After-Hours Movers 09/05: (NTGN) (IMUX) (DOCU) Higher; (DOMO) (MDLA) (PD) Lower (more...)

Today's After-Hours Movers

Domo, Inc. (Nasdaq: DOMO) 36.9% LOWER; Q2 results and weak outlook

Neon Therapeutics, Inc. (NASDAQ: NTGN) 27.8% HIGHER; announced publication in the scientific journal Immunity of a breakthrough process for predicting which neoantigens will be presented by MHC class II molecules in the tumor microenvironment. Predicting the relevant cancer-specific antigens is a crucial precursor to developing immunotherapies that effectively train T cells to traffic to the tumor and destroy malignant cells. In the paper, titled Defining HLA-II ligand processing and binding rules with... More

lululemon athletica (LULU) Tops Q2 EPS by 7c, Offers Q3 and FY Guidance

lululemon athletica (NASDAQ: LULU) reported Q2 EPS of $0.96, $0.07 better than the analyst estimate of $0.89. Revenue for the quarter came in at $883 million versus the consensus estimate of $843.65 million.

GUIDANCE:

lululemon athletica sees Q3 2019 EPS of $0.90-$0.92, versus the consensus of $0.90. lululemon athletica sees Q3 2019 revenue of $880-890 million, versus... More